摘要
目的探讨脑胶质瘤患者血清血管内皮生长因子(VEGF)及其受体Flt-1和KDR水平变化,为评价脑胶质瘤治疗效果,判断预后寻找一种科学的生物学标志物。方法收集治疗前后脑胶质瘤患者、脑转移癌患者和健康对照者血清,进行VEGF,Flt-1和KDR水平的检测,SPSS11.5统计软件包对数据进行t检验和相关分析。结果治疗前脑胶质瘤和脑转移瘤患者血清VEGF水平明显高于健康对照组;脑胶质瘤患者组和脑转移瘤患者组血清Flt-1水平明显高于健康对照组;脑胶质瘤患者组血清KDR水平明显高于健康对照组;治疗后缓解的脑胶质瘤患者组VEGF和Flt-1水平明显低于治疗前,差异均有统计学意义。VEGF与Flt-1和KDR有显著的相关性。结论脑胶质瘤患者血清中VEGF及其受体的检测,可作为脑胶质瘤辅助诊断、治疗效果监测和预后判断的重要生物学指标。
Objective To evaluate the serum changes in glioma patients, and in relations with clinicopathalogy parameters response to treatment and survival in patients with glioma via the examination of the significance of serum VEGF, Flt-i and KDR levels. Methods Serum VEGF,Flt-1 and KDR levels were analyzed in patients of glioma before and after treatment, and patients with brain metastasis, as well as in healthy controls. Serum VEGF, Flt-1 and KDR levels were assessed by Enzyme-Linked Immunosorbent Assay（ELISA） and the data were processed by SPSS 11.5 for t-test and relevant analyses. Results Serum VEGF, Flt-1 and KDR levels were higher in patients with glioma than in healthy control （P =0.001, P =0.043 and P =0.045 respectively）. Significant difference on levels of VEGF was found （P =0.032） comparing glioma group with brain metastasis group. The pretherapeutic serum levels of VEGF and Flt-1 were significantly different with disease recurrence or persistence after treatment （P =0.026 and P =0.038）. There was significant correlation between the serum levels of VEGF correlated and that of Flt-1 and KDR （r =0.456 P 〈0.01 and r =0.398 P 〈0.02）. Conclusions The serum levels of VEGF, and Flt-1 have potential usefulness as biologic markers in the diagnosis and evaluation of therapeutic effect of glioma.
出处
《肿瘤研究与临床》
CAS
2006年第12期812-814,共3页
Cancer Research and Clinic
